Dusseldorf - Delayed Quote EUR

Ocugen Inc (2H51.DU)

0.6354

+0.0014

+(0.22%)

As of 12:30:20 PM GMT+2. Market Open.

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

We recently published a list of the 11 Best Penny Stocks to Invest in Under $1. In this article, we are going to take a look at where Ocugen Inc. (NASDAQ:OCGN) stands against other penny stocks to invest in under $1. Earlier on February 12 this year, Chief Investment Officer at Cetera Financial Group, Gene […]

Insider Monkey 11 days ago

OCGN
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy. “I look forward to sharing more on how Ocugen’s modifier gene therapy platform can pot

GlobeNewswire 19 days ago

OCGN
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks last month

OCGN
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

The open-label trial aims to evaluate the drug's safety when administered via intravitreal injection.

Clinical Trials Arena last month

OCGN
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data follo

GlobeNewswire last month

OCGN
Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY...

Simply Wall St. last month

OCGN
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market competition.

GuruFocus.com last month

OCGN
Q4 2024 Ocugen Inc Earnings Call

Q4 2024 Ocugen Inc Earnings Call

Thomson Reuters StreetEvents last month

OCGN
Ocugen (OCGN) Q4 2024 Earnings Call Transcript

OCGN earnings call for the period ending December 31, 2024.

Motley Fool last month

OCGN
Ocugen: Q4 Earnings Snapshot

MALVERN, Pa. AP) — Ocugen, Inc. OCGN) on Wednesday reported a loss of $13.9 million in its fourth quarter.

Associated Press Finance last month

OCGN
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable

GlobeNewswire last month

OCGN
Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

Ocugen (OCGN) said Monday that the European Medicines Agency's Committee for Advanced Therapies issu

PREMIUM
MT Newswires last month

OCGN
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) for OCU410 and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being develope

GlobeNewswire last month

OCGN
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission. The GARDian trial for OCU410ST demonstrated: A favorab

GlobeNewswire last month

OCGN
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings an

GlobeNewswire 2 months ago

OCGN
Why Ocugen (OCGN) Is Advancing Today

Ocugen (OCGN) is climbing 5% after investment bank H.C. Wainwright raised its price target on the shares to $8 from $7. OCGN, whose stock is currently trading around 69 cents, develops gene therapies for diseases the affect eyes. Why H.C. Wainwright IS Bullish on OCGN The results of the first stage of a Phase 1/2 […]

Insider Monkey 2 months ago

OCGN
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse events related to OCU410, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization Subjects showed considerably slower lesion growth (44%) from baseline in treated eyes versus untreated fellow eyes at 9 months in follow-up dat

GlobeNewswire 2 months ago

OCGN
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) for OCU400 Advanced Therapy Medicinal Product (ATMP) classification. OCU400 is the first gene therapy to

GlobeNewswire 2 months ago

OCGN
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q 2025 MALVERN, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. Food and Drug Administra

GlobeNewswire 2 months ago

OCGN
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

The open-label, dose-escalation trial will explore the effects of different dosage levels of OCU200.

Clinical Trials Arena 3 months ago

OCGN

Performance Overview

Return	2H51.DU	S&P 500 (^GSPC)
YTD	-25.03%	-6.06%
1-Year	-46.96%	+8.34%
3-Year	-68.36%	+28.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocugen Inc (2H51.DU)

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs

Q4 2024 Ocugen Inc Earnings Call

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

Ocugen: Q4 Earnings Snapshot

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Why Ocugen (OCGN) Is Advancing Today

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

Performance Overview